Changes in regulatory B cells and their relationship with rheumatoid arthritis disease activity
Changes in regulatory B cells and their relationship with rheumatoid arthritis disease activity
复制标题
DOI：
10.1007/s10238-014-0310-9
复制
发表时间：
2015-08-01
影响因子：
4.6
通讯作者：
Shen, Bo
中科院分区：
文献类型：
--
作者：
Cui, Donghua;Zhang, Lili;Shen, Bo
B细胞的调节亚群（Bregs）调节自身免疫、癌症和其他炎症疾病的免疫反应。在本研究中，我们研究了类风湿关节炎（RA）患者循环Breg细胞的数量。我们评估了59名RA患者和25名健康对照者。用流式细胞术分析外周血单个核细胞中CD19(+)CD5(+)CD1d(hi) B细胞和分泌颗粒酶B细胞CD19(+)CD5(+)GzmB（+）。采用酶联免疫吸附试验（ELISA）检测血清白细胞介素10 （IL-10）、白细胞介素21 （IL-21）、颗粒酶B （GzmB）。与对照组相比，我们发现RA患者的CD19(+)CD5(+)CD1d(hi) B细胞比例降低。CD19(+)CD5(+)CD1d(hi) B细胞数量与DAS28呈负相关（P < 0.05）。RA患者血清IL-10和IL-21浓度显著低于健康对照组（P < 0.05）。相反，RA患者的CD19(+)CD5(+)GzmB(+) B细胞数量显著增加（P < 0.05）， CD19(+)CD5(+)GzmB(+) B细胞数量与DAS28、IL-21或GzmB无关（P < 0.05）。有趣的是，RA患者IL-21与GzmB水平呈正相关（P < 0.05）。我们的数据表明CD19(+)CD5(+)CD1d(hi) B细胞影响RA疾病的活性。CD19(+)CD5(+)GzmB(+) B细胞可能参与RA的发生和进展。我们的数据强烈提示Bregs在RA中的作用，并且Bregs可能是一种可行的RA疾病治疗策略。
Regulatory subsets of B cells (Bregs) modulate immune responses in autoimmunity, cancer, and other inflammation diseases. In the present study, we investigated the numbers of circulating Breg cells in patients with rheumatoid arthritis (RA). We evaluated 59 RA patients and 25 healthy controls. CD19(+)CD5(+)CD1d(hi) B cells and granzyme B-secreting B cells (CD19(+)CD5(+)GzmB(+)) were analyzed by flow cytometry in peripheral blood mononuclear cells. We detected serum interleukin 10 (IL-10), interleukin 21 (IL-21), granzyme B (GzmB) using enzyme-linked immunosorbent assay (ELISA). Compared to control subjects, we found a decreased proportion of CD19(+)CD5(+)CD1d(hi) B cells in RA patients. The number of CD19(+)CD5(+)CD1d(hi) B cells negatively correlated with DAS28 (P < 0.05). Moreover, serum IL-10 and IL-21 concentrations were significantly lower in RA patients compared to healthy controls (P < 0.05). Conversely, the number of CD19(+)CD5(+)GzmB(+) B cells was significantly higher in RA patients (P < 0.05), and the number of CD19(+)CD5(+)GzmB(+) B cells did not correlate with DAS28, IL-21, or GzmB (P > 0.05, all). Interestingly, IL-21 and GzmB levels positively correlated in RA patients (P < 0.05). Our data indicate that CD19(+)CD5(+)CD1d(hi) B cells influence RA disease activity. CD19(+)CD5(+)GzmB(+) B cells may be involved in RA development and progression. Our data strongly suggest a role for Bregs in RA, and Bregs may be a viable therapeutic strategy for RA disease.